About Sanguine Life Sciences
Sanguine Corporation is keenly focused on pioneering the development and commercialization of innovative perfluorocarbon-based therapies and medical devices.
PHER-O2
Its lead product, PHER-02, is an intravenous perfluorocarbon emulsion that is highly efficient at dissolving and delivering oxygen to tissues. Such properties make PHER-02 an ideal product for the treatment of a myriad of medical conditions with high morbidity and/or mortality directly resulting from a lack of oxygen at the cellular level.
Our Philosophy
Sanguine’s philosophy is to develop products that have a sound scientific basis and that have demonstrated Proof of Concept, while adhering to the highest industry standards of product development. The Company achieves its designated objectives through two primary means:
- The employment of organic methodologies.
- Strategic alliances through carefully managed partnerships with well positioned companies, universities, research institutions and government agencies.
News & Updates
